Mosaic HIV envelope immunogenic polypeptides

Patent metadata

Field	Value
Publication number	US-9855329-B2
Application number	US-201415025806-A
Country	US
Kind code	B2
Filing date	Sep 30, 2014
Priority date	Sep 30, 2013
Publication date	Jan 2, 2018
Grant date	Jan 2, 2018

Abstract

Disclosed herein are mosaic HIV envelope (Env) polypeptides that can elicit an immune response to HIV (such as cytotoxic T cell (CTL), helper T cell, and/or humoral responses). Also disclosed are sets of the disclosed mosaic Env polypeptides, which include two or more (for example, three) of the polypeptides. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject infected with HIV or at risk of HIV infection. In some embodiments, the methods include inducing an immune response to HIV in a subject comprising administering to the subject at least one (such as two, three, or more) of the immunogenic polypeptides or at least one (such as two, three, or more) nucleic acids encoding at least one of the immunogenic polypeptides disclosed herein.

First claim

We claim:

1. A set of isolated immunogenic polypeptides comprising:
polypeptides comprising the amino acid sequences set forth as SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3;
polypeptides comprising the amino acid sequences set forth as SEQ ID NO: 1, SEQ ID NO: 4, and SEQ ID NO: 5; or
polypeptides comprising the amino acid sequences set forth as SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.

2. An isolated immunogenic polypeptide comprising the amino acid sequence set forth as any one of SEQ ID NOs: 1-8 or an amino acid sequence having at least 95% identity to the amino acid sequence set forth as any one of SEQ ID NOs: 1-8.

3. The isolated immunogenic polypeptide of claim 2 , wherein the polypeptide consists of the amino acid sequence set forth as any one of SEQ ID NOs: 1-8.

4. A set of isolated immunogenic polypeptides comprising two or more of the polypeptides of claim 2 .

5. The set of isolated immunogenic polypeptides of claim 4 , wherein the two or more polypeptides are selected from polypeptides consisting of the amino acid sequences set forth as any one of SEQ ID NOs: 1-8.

6. A pharmaceutical composition comprising:
one or more of the isolated immunogenic polypeptides of claim 2 ; and
a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 6 , further comprising one or more of an adjuvant, a detergent, a micelle-forming agent, and an oil.

8. A pharmaceutical composition comprising:
the set of immunogenic polypeptides of claim 4 ; and
a pharmaceutically acceptable carrier.

9. A method for eliciting an immune response to human immunodeficiency virus (HIV) in a subject, comprising administering to the subject an effective amount of:
the set of immunogenic polypeptides of claim 4 ;
thereby eliciting an immune response to HIV in the subject.

10. The method of claim 9 , wherein the polypeptides in the set are administered to the subject simultaneously, substantially simultaneously, or sequentially.

11. The method of claim 9 , further comprising administering to the subject a therapeutically effective amount of an anti-viral agent.

12. A method for eliciting an immune response to human immunodeficiency virus (HIV) in a subject, comprising administering to the subject an effective amount of the set of immunogenic polypeptides of claim 1 , thereby eliciting an immune response to HIV in the subject.

13. A method for eliciting an immune response to human immunodeficiency virus (HIV) in a subject, comprising administering to the subject an effective amount of the immunogenic polypeptide of claim 2 , thereby eliciting an immune response to HIV in the subject.

Assignees

• Los Alamos Nat Security Llc
• Univ Duke
• Dana Farber Cancer Inst Inc
• Dana-Farber Cancer Inst

Inventors

• Korber Bette T M
• Gnanakaran S
• Perkins Simon
• Sodroski Joseph
• Haynes Barton

Classifications

• C07K16/1145

  Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

• C07K16/1063

  Chemistry & Metallurgy · mapped topic

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K14/162

  env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title